Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Piramal Launches Trial Material Packaging Capacity In UK
The 13,000 square feet primary and secondary trial packaging unit that expands the active pharmaceutical ingredient (API) site in Morpeth, Humberside, will serve as one stop shop for
The 13,000 square feet primary and secondary trial packaging unit that expands the active pharmaceutical ingredient (API) site in Morpeth, Humberside, will serve as one stop shop for
The states which are up against Wyeth are California, Delaware, the District of Columbia, Florida, Illinois, Indiana, Louisiana, Massachusetts, Michigan, New Hampshire, New York, Nevada, Tennessee, Texas, Virginia,
The acquisition is subject to clearance under the Hart-Scott-Rodino Antitrust Improvement Act and other customary closing conditions. Cowen and Company is acting as exclusive financial advisor to Victory
“TriLink provides high quality reagents which have contributed to the excellent performance of our eSensor products in the marketplace to date,” said Osmetech Molecular Diagnostics chief operating officer,
Henry Nordhoff, who had served as its CEO since 1994, is now non-executive chairman following his re-election to the board at the company’s annual meeting of stockholders last
WellCare will pay a total civil penalty of $10 million, and $1 for disgorgement, in addition to post-judgment interest. The initial payment of $2.5 million will be paid
Ministry of Health aims to reduce the country’s import bill of $1.8 billion due to 70% of imported pharmaceutical products that was noticed in 2007. It seeks to
Last year, the company acquired Canadian and US licensing rights to the drug Xenazine, by purchasing Prestwick Pharmaceuticals. It was the company’s first foray into the CNS disorder
In addition to implementing cost cutting measures, particularly in the area of executive compensation and other operating areas, the company is also contemplating the separation of its OTC
The parent company took the decision as MediCult A/S – a leader in Assisted Reproductive Technologies – did not reach the required share threshold within the set timeframe